Galectin Therapeutics, Inc.
USPTO PatentsView assignee record - 13 granted patents across 4 technology areas, recorded in grant years 2015–2022. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61K (Preparations FOR Medical, Dental OR Toiletry Purposes).
The verdict
According to USPTO PatentsView, Galectin ranks #21,165 of 49,997 tracked US assignees by granted-patent volume, with 13 patents across 4 technology areas.
- #21,165
- of 49,997 US assignees by volume
- 25th percentile
- by Innovation Score (27.7/100)
- 16.5
- avg claims per patent
- -70%
- grant velocity, last 5 yrs
USPTO PatentsView assignee plate
Corpus R21165 · US Corporation #21,165 · 13 grants
GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-DROP · BOOK-FULL
- GRANTS-MICRO 13 grants
- MID-PACK #21,165/49,997
- PHOTO-FINISH Fuchs Petrolub SE
- CPC-NARROW A61K · 4 areas
- INNOV-THIN 27.7/100
- CLAIMS-RICH 16.5 claims/avg
- TYPE-USCORP US Corporation
- VEL-DROP -70% vel
- BOOK-FULL 10/10 fields
Nearest grant-volume peer: Fuchs Petrolub SE (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How Galectin’s 27.7 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around Galectin
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- Galectin Therapeutics · this assignee 28
Galectin Therapeutics · this assignee
28 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Galectin's Innovation Score is 27.7/100 (25th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for Galectin?
Each dot is one of Galectin’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Galectin’s own 16.5 claims/patent is at or below the 16.5 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.
Where Galectin's grants concentrate
Galectin Therapeutics, Inc. is a focused PatentsView assignee: 4 CPC subclasses with 100% of grants classified under A61K (Preparations FOR Medical, Dental OR Toiletry Purposes). Peak complete grant year is 2018 (3 grants) versus a trough of 1 in 2016. By volume, Galectin sits between Fuchs Petrolub SE and Genome Research Limited.
Galectin's three-year grant acceleration
Galectin Therapeutics, Inc. shows 1 grants in 2022–2024 against only 4 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Who files at Galectin's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Fuchs Petrolub SE
Fuchs Petrolub SE
13 patents
- Fulcrum Bioenergy
Fulcrum BioEnergy, Inc.
13 patents
- Furukawa Rock Dri…
Furukawa Rock Drill Co., Ltd.
13 patents
- G W Lisk
G.W. Lisk Company, Inc.
13 patents
- General Dynamics…
General Dynamics Ordnance AND Tactical SYSTEMS—CANADA, Inc.
13 patents
- General Test Syst…
General Test Systems Inc.
13 patents
- Genmab B V
Genmab B.V.
13 patents
- Genome Research
Genome Research Limited
13 patents
- Galectin Therapeu… ◀
Galectin Therapeutics, Inc.
13 patents
What this shows Galectin holds 13 patents at rank #21,164, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Galectin
By rank, the assignees closest to #21,164 in granted patent volume.
- Fuchs Petrolub SE #21,160 · 13 patents
- Fulcrum BioEnergy, Inc. #21,161 · 13 patents
- Furukawa Rock Drill Co., Ltd. #21,162 · 13 patents
- G.W. Lisk Company, Inc. #21,163 · 13 patents
- General Dynamics Ordnance AND Tactical SYSTEMS—CANADA, Inc. #21,165 · 13 patents
- General Test Systems Inc. #21,166 · 13 patents
- Genmab B.V. #21,167 · 13 patents
- Genome Research Limited #21,168 · 13 patents
Leaders in A61K (Preparations FOR Medical)
Other assignees with the most granted patents in Galectin's primary technology class.
- The Regents of the University of California 1,779 in class
- L'Oreal 1,250 in class
- Novartis AG 988 in class
- The Procter & Gamble Company 985 in class
- The Board of Regents of the University of Texas System 950 in class
- The United States of America, as represented by the Secretary, Department of Health and Human Services 813 in class
- The Trustees of the University of Pennsylvania 768 in class
- Merck Sharp & Dohme LLC 760 in class
Galectin's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
28 25th percentile higher than 25% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 2 | 15.4% |
| 2016 | 1 | 7.7% |
| 2017 | 2 | 15.4% |
| 2018 | 3 | 23.1% |
| 2019 | 2 | 15.4% |
| 2020 | 2 | 15.4% |
| 2022 | 1 | 7.7% |
Which technologies does Galectin Therapeutics, Inc. patent most?
Top 4 of 4 technology areas
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
Galectin Therapeutics, Inc.'s patent record in context - here's where to go next.
- Galectin Therapeutics, Inc.'s lead technology class is A61K (Preparations FOR Medical, Dental OR Toiletry Purposes), 100% of its portfolio - see every assignee active in that class. Explore A61K
- Ranked #21,165 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare Galectin Therapeutics, Inc. against Fuchs Petrolub SE, an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 27.7/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.